Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Caravan
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Factor 1A, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Caravan is a co-founder of Factor 1A, LLC and holds equity in the private company. Factor 1A, LLC is developing fibrin binding technology for imaging probes and has patented compound EP-2104R. The research uses new methods to modulate the image signal from injected agents that bind to specific molecular targets, making them more visible, and will enable important new applications in biomedical imaging that can be immediately utilized with certain FDA-approved contrast agents. One of the contrast agents used in the research is EP-2104R, which is covered by patent owned by Factor 1A. The results of this study could therefore be of interest to the company. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company’s interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Improved MRI Contrast Agent Visibility Through Contrast Agent Manipulation
PROJECT NARRATIVE This project will develop novel MRI methods to bring MRI from its conventional role of taking pictures of tissue and organs to probing the workings of the body on the molecular level, which is a long sought after approach that is technically challenging. We approach it with new methods to modulate the image signal from injected agents that bind to specific molecular targets, thus making them more visible. This has great potential to inform clinicians on the state of disease processes.
Filed on October 09, 2018.
Tell us what you know about Peter Caravan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Peter Caravan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Brigham and Women's Hospital | Conflict of Interest | Catalyst Medical | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Brigham and Women's Hospital | Conflict of Interest | Collagen Medical | $10,000 - $19,999 |
| Peter Caravan | Brigham and Women's Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.